Loading…
High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice
Identifying the impact of a patient's ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy wit...
Saved in:
| Published in: | Clinical and molecular hepatology 2013, 19(1), , pp.60-69 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c523t-cf40b99ed7e3b1aff8fbf83f22b379cc4563466814e46e883dfaa13307ef4ac93 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c523t-cf40b99ed7e3b1aff8fbf83f22b379cc4563466814e46e883dfaa13307ef4ac93 |
| container_end_page | 69 |
| container_issue | 1 |
| container_start_page | 60 |
| container_title | Clinical and molecular hepatology |
| container_volume | 19 |
| creator | Heo, Nae-Yun Lim, Young-Suk Lee, Han Chu Lee, Yung Sang Kim, Kang Mo Byun, Kwan Soo Han, Kwang-Hyub Lee, Kwan Sik Paik, Seung Woon Yoon, Seung Kew Suh, Dong Jin |
| description | Identifying the impact of a patient's ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investigated in the present study.
The clinical data of 272 treatment-naïve Korean CHC patients who were treated in a community-based clinical trial (Clinical Trial group; n=51) and in clinical practice (Cohort group; n=221), were analyzed and compared. All were treated with standard protocols of peginterferon alfa-2a plus ribavirin therapy.
For patients with hepatitis C virus (HCV) genotype 1, the sustained virological response (SVR) rates in the Clinical Trial and Cohort groups were 81% (21/26) and 55% (58/106), respectively, by intention-to-treat (ITT) analysis (P=0.02), and 100% (13/13) and 80% (32/40), respectively, in treatment-adherent patients (P=0.18). For patients with HCV genotype 2, the SVR rates in these two groups were 96% (24/25) and 88% (101/115), respectively, by ITT analysis (P=0.31). Adherence and treatment duration were independent predictors of SVR for genotypes 1 and 2, respectively (P |
| doi_str_mv | 10.3350/cmh.2013.19.1.60 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_492427</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d3e8c704287a4f7291cd847034fd8ff2</doaj_id><sourcerecordid>3126718788</sourcerecordid><originalsourceid>FETCH-LOGICAL-c523t-cf40b99ed7e3b1aff8fbf83f22b379cc4563466814e46e883dfaa13307ef4ac93</originalsourceid><addsrcrecordid>eNpVUk1r3DAQFaWlCdvceyqCXnpZR1-25EshLG2zJFAoKfQmZHm01sZruZJ3S87945V3k9DoMsPozZun0UPoPSUF5yW5tLuuYITygtYFLSryCp0zpuSSqfLX66dcMnWGLlLaknwkYWXN36IzxnOsKD1Hf6_9psPgHNjJH2CAlHBweISNHyaIDmIYsOmdWTKDx36fcPSNOfjoBzx1EM34gHN6EyKYAY9m8jBMCf_xU4dtl5u9xR3M9cknvJqxtve5ano8RpOHWniH3jjTJ7h4jAv08-uXu9X18vb7t_Xq6nZpS8anpXWCNHUNrQTeUOOcco1T3DHWcFlbK8qKi6pSVICoQCneOmMo50SCE8bWfIE-nXiH6PS99ToYf4yboO-jvvpxt9aiZoLJDF2foG0wWz1GvzPx4Yg_FkLcaBOz9h50y0FZSURetxFOspraVglJuHCtco5lrs8nrnHf7KC1eUHR9C9IX94MvsuSDppX-Q_LWczHR4IYfu8hTXob9nHIq9KcskpSJfNrF4icUDaGlCK45wmU6NkwOhtGz4bRtNZUVyS3fPhf2XPDkz34P1ygvrk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3126718788</pqid></control><display><type>article</type><title>High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Heo, Nae-Yun ; Lim, Young-Suk ; Lee, Han Chu ; Lee, Yung Sang ; Kim, Kang Mo ; Byun, Kwan Soo ; Han, Kwang-Hyub ; Lee, Kwan Sik ; Paik, Seung Woon ; Yoon, Seung Kew ; Suh, Dong Jin</creator><creatorcontrib>Heo, Nae-Yun ; Lim, Young-Suk ; Lee, Han Chu ; Lee, Yung Sang ; Kim, Kang Mo ; Byun, Kwan Soo ; Han, Kwang-Hyub ; Lee, Kwan Sik ; Paik, Seung Woon ; Yoon, Seung Kew ; Suh, Dong Jin</creatorcontrib><description>Identifying the impact of a patient's ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investigated in the present study.
The clinical data of 272 treatment-naïve Korean CHC patients who were treated in a community-based clinical trial (Clinical Trial group; n=51) and in clinical practice (Cohort group; n=221), were analyzed and compared. All were treated with standard protocols of peginterferon alfa-2a plus ribavirin therapy.
For patients with hepatitis C virus (HCV) genotype 1, the sustained virological response (SVR) rates in the Clinical Trial and Cohort groups were 81% (21/26) and 55% (58/106), respectively, by intention-to-treat (ITT) analysis (P=0.02), and 100% (13/13) and 80% (32/40), respectively, in treatment-adherent patients (P=0.18). For patients with HCV genotype 2, the SVR rates in these two groups were 96% (24/25) and 88% (101/115), respectively, by ITT analysis (P=0.31). Adherence and treatment duration were independent predictors of SVR for genotypes 1 and 2, respectively (P<0.01 for each). Korean patients with CHC achieved high SVR rates with peginterferon alfa-2a plus ribavirin in both the clinical trial and clinical practice settings.
Measures to raise adherence to standard therapy in clinical practice may improve the SVR rates in these patients as effectively as adding protease inhibitors, thus obviating the need for the latter.</description><identifier>ISSN: 2287-2728</identifier><identifier>EISSN: 2287-285X</identifier><identifier>DOI: 10.3350/cmh.2013.19.1.60</identifier><identifier>PMID: 23593611</identifier><language>eng</language><publisher>Korea (South): Korean Association for the Study of the Liver</publisher><subject>Adolescent ; Adult ; Aged ; Antiviral Agents - therapeutic use ; Antiviral drugs ; Asian Continental Ancestry Group ; Asian people ; Clinical medicine ; Clinical trials ; Cohort Studies ; Combination therapy ; Drug dosages ; Drug Therapy, Combination ; Female ; Genotype ; Genotype & phenotype ; Hepacivirus - genetics ; Hepatitis C ; Hepatitis C, Chronic - drug therapy ; Humans ; Interferon-alpha - therapeutic use ; Liver cancer ; Liver cirrhosis ; Liver diseases ; Male ; Medication adherence ; Middle Aged ; Odds Ratio ; Original ; Patients ; Peginterferon alfa-2a ; Polyethylene Glycols - therapeutic use ; Predictive Value of Tests ; Recombinant Proteins - therapeutic use ; Republic of Korea ; Ribavirin ; Ribavirin - therapeutic use ; Ribonucleic acid ; RNA ; RNA, Viral - genetics ; Treatment Outcome ; Young Adult ; 내과학</subject><ispartof>Clinical and Molecular Hepatology, 2013, 19(1), , pp.60-69</ispartof><rights>2013. This work is published under http://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2013 by The Korean Association for the Study of the Liver 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c523t-cf40b99ed7e3b1aff8fbf83f22b379cc4563466814e46e883dfaa13307ef4ac93</citedby><cites>FETCH-LOGICAL-c523t-cf40b99ed7e3b1aff8fbf83f22b379cc4563466814e46e883dfaa13307ef4ac93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622857/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3126718788?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,44566,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23593611$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001752027$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Heo, Nae-Yun</creatorcontrib><creatorcontrib>Lim, Young-Suk</creatorcontrib><creatorcontrib>Lee, Han Chu</creatorcontrib><creatorcontrib>Lee, Yung Sang</creatorcontrib><creatorcontrib>Kim, Kang Mo</creatorcontrib><creatorcontrib>Byun, Kwan Soo</creatorcontrib><creatorcontrib>Han, Kwang-Hyub</creatorcontrib><creatorcontrib>Lee, Kwan Sik</creatorcontrib><creatorcontrib>Paik, Seung Woon</creatorcontrib><creatorcontrib>Yoon, Seung Kew</creatorcontrib><creatorcontrib>Suh, Dong Jin</creatorcontrib><title>High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice</title><title>Clinical and molecular hepatology</title><addtitle>Clin Mol Hepatol</addtitle><description>Identifying the impact of a patient's ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investigated in the present study.
The clinical data of 272 treatment-naïve Korean CHC patients who were treated in a community-based clinical trial (Clinical Trial group; n=51) and in clinical practice (Cohort group; n=221), were analyzed and compared. All were treated with standard protocols of peginterferon alfa-2a plus ribavirin therapy.
For patients with hepatitis C virus (HCV) genotype 1, the sustained virological response (SVR) rates in the Clinical Trial and Cohort groups were 81% (21/26) and 55% (58/106), respectively, by intention-to-treat (ITT) analysis (P=0.02), and 100% (13/13) and 80% (32/40), respectively, in treatment-adherent patients (P=0.18). For patients with HCV genotype 2, the SVR rates in these two groups were 96% (24/25) and 88% (101/115), respectively, by ITT analysis (P=0.31). Adherence and treatment duration were independent predictors of SVR for genotypes 1 and 2, respectively (P<0.01 for each). Korean patients with CHC achieved high SVR rates with peginterferon alfa-2a plus ribavirin in both the clinical trial and clinical practice settings.
Measures to raise adherence to standard therapy in clinical practice may improve the SVR rates in these patients as effectively as adding protease inhibitors, thus obviating the need for the latter.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>Asian Continental Ancestry Group</subject><subject>Asian people</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Cohort Studies</subject><subject>Combination therapy</subject><subject>Drug dosages</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Genotype</subject><subject>Genotype & phenotype</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Humans</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Medication adherence</subject><subject>Middle Aged</subject><subject>Odds Ratio</subject><subject>Original</subject><subject>Patients</subject><subject>Peginterferon alfa-2a</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Predictive Value of Tests</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Republic of Korea</subject><subject>Ribavirin</subject><subject>Ribavirin - therapeutic use</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>RNA, Viral - genetics</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><subject>내과학</subject><issn>2287-2728</issn><issn>2287-285X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpVUk1r3DAQFaWlCdvceyqCXnpZR1-25EshLG2zJFAoKfQmZHm01sZruZJ3S87945V3k9DoMsPozZun0UPoPSUF5yW5tLuuYITygtYFLSryCp0zpuSSqfLX66dcMnWGLlLaknwkYWXN36IzxnOsKD1Hf6_9psPgHNjJH2CAlHBweISNHyaIDmIYsOmdWTKDx36fcPSNOfjoBzx1EM34gHN6EyKYAY9m8jBMCf_xU4dtl5u9xR3M9cknvJqxtve5ano8RpOHWniH3jjTJ7h4jAv08-uXu9X18vb7t_Xq6nZpS8anpXWCNHUNrQTeUOOcco1T3DHWcFlbK8qKi6pSVICoQCneOmMo50SCE8bWfIE-nXiH6PS99ToYf4yboO-jvvpxt9aiZoLJDF2foG0wWz1GvzPx4Yg_FkLcaBOz9h50y0FZSURetxFOspraVglJuHCtco5lrs8nrnHf7KC1eUHR9C9IX94MvsuSDppX-Q_LWczHR4IYfu8hTXob9nHIq9KcskpSJfNrF4icUDaGlCK45wmU6NkwOhtGz4bRtNZUVyS3fPhf2XPDkz34P1ygvrk</recordid><startdate>20130301</startdate><enddate>20130301</enddate><creator>Heo, Nae-Yun</creator><creator>Lim, Young-Suk</creator><creator>Lee, Han Chu</creator><creator>Lee, Yung Sang</creator><creator>Kim, Kang Mo</creator><creator>Byun, Kwan Soo</creator><creator>Han, Kwang-Hyub</creator><creator>Lee, Kwan Sik</creator><creator>Paik, Seung Woon</creator><creator>Yoon, Seung Kew</creator><creator>Suh, Dong Jin</creator><general>Korean Association for the Study of the Liver</general><general>The Korean Association for the Study of the Liver</general><general>대한간학회</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope><scope>ACYCR</scope></search><sort><creationdate>20130301</creationdate><title>High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice</title><author>Heo, Nae-Yun ; Lim, Young-Suk ; Lee, Han Chu ; Lee, Yung Sang ; Kim, Kang Mo ; Byun, Kwan Soo ; Han, Kwang-Hyub ; Lee, Kwan Sik ; Paik, Seung Woon ; Yoon, Seung Kew ; Suh, Dong Jin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c523t-cf40b99ed7e3b1aff8fbf83f22b379cc4563466814e46e883dfaa13307ef4ac93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>Asian Continental Ancestry Group</topic><topic>Asian people</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Cohort Studies</topic><topic>Combination therapy</topic><topic>Drug dosages</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Genotype</topic><topic>Genotype & phenotype</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Humans</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Medication adherence</topic><topic>Middle Aged</topic><topic>Odds Ratio</topic><topic>Original</topic><topic>Patients</topic><topic>Peginterferon alfa-2a</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Predictive Value of Tests</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Republic of Korea</topic><topic>Ribavirin</topic><topic>Ribavirin - therapeutic use</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>RNA, Viral - genetics</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><topic>내과학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Heo, Nae-Yun</creatorcontrib><creatorcontrib>Lim, Young-Suk</creatorcontrib><creatorcontrib>Lee, Han Chu</creatorcontrib><creatorcontrib>Lee, Yung Sang</creatorcontrib><creatorcontrib>Kim, Kang Mo</creatorcontrib><creatorcontrib>Byun, Kwan Soo</creatorcontrib><creatorcontrib>Han, Kwang-Hyub</creatorcontrib><creatorcontrib>Lee, Kwan Sik</creatorcontrib><creatorcontrib>Paik, Seung Woon</creatorcontrib><creatorcontrib>Yoon, Seung Kew</creatorcontrib><creatorcontrib>Suh, Dong Jin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><collection>Korean Citation Index (Open Access)</collection><jtitle>Clinical and molecular hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Heo, Nae-Yun</au><au>Lim, Young-Suk</au><au>Lee, Han Chu</au><au>Lee, Yung Sang</au><au>Kim, Kang Mo</au><au>Byun, Kwan Soo</au><au>Han, Kwang-Hyub</au><au>Lee, Kwan Sik</au><au>Paik, Seung Woon</au><au>Yoon, Seung Kew</au><au>Suh, Dong Jin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice</atitle><jtitle>Clinical and molecular hepatology</jtitle><addtitle>Clin Mol Hepatol</addtitle><date>2013-03-01</date><risdate>2013</risdate><volume>19</volume><issue>1</issue><spage>60</spage><epage>69</epage><pages>60-69</pages><issn>2287-2728</issn><eissn>2287-285X</eissn><abstract>Identifying the impact of a patient's ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investigated in the present study.
The clinical data of 272 treatment-naïve Korean CHC patients who were treated in a community-based clinical trial (Clinical Trial group; n=51) and in clinical practice (Cohort group; n=221), were analyzed and compared. All were treated with standard protocols of peginterferon alfa-2a plus ribavirin therapy.
For patients with hepatitis C virus (HCV) genotype 1, the sustained virological response (SVR) rates in the Clinical Trial and Cohort groups were 81% (21/26) and 55% (58/106), respectively, by intention-to-treat (ITT) analysis (P=0.02), and 100% (13/13) and 80% (32/40), respectively, in treatment-adherent patients (P=0.18). For patients with HCV genotype 2, the SVR rates in these two groups were 96% (24/25) and 88% (101/115), respectively, by ITT analysis (P=0.31). Adherence and treatment duration were independent predictors of SVR for genotypes 1 and 2, respectively (P<0.01 for each). Korean patients with CHC achieved high SVR rates with peginterferon alfa-2a plus ribavirin in both the clinical trial and clinical practice settings.
Measures to raise adherence to standard therapy in clinical practice may improve the SVR rates in these patients as effectively as adding protease inhibitors, thus obviating the need for the latter.</abstract><cop>Korea (South)</cop><pub>Korean Association for the Study of the Liver</pub><pmid>23593611</pmid><doi>10.3350/cmh.2013.19.1.60</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2287-2728 |
| ispartof | Clinical and Molecular Hepatology, 2013, 19(1), , pp.60-69 |
| issn | 2287-2728 2287-285X |
| language | eng |
| recordid | cdi_nrf_kci_oai_kci_go_kr_ARTI_492427 |
| source | Publicly Available Content (ProQuest); PubMed Central |
| subjects | Adolescent Adult Aged Antiviral Agents - therapeutic use Antiviral drugs Asian Continental Ancestry Group Asian people Clinical medicine Clinical trials Cohort Studies Combination therapy Drug dosages Drug Therapy, Combination Female Genotype Genotype & phenotype Hepacivirus - genetics Hepatitis C Hepatitis C, Chronic - drug therapy Humans Interferon-alpha - therapeutic use Liver cancer Liver cirrhosis Liver diseases Male Medication adherence Middle Aged Odds Ratio Original Patients Peginterferon alfa-2a Polyethylene Glycols - therapeutic use Predictive Value of Tests Recombinant Proteins - therapeutic use Republic of Korea Ribavirin Ribavirin - therapeutic use Ribonucleic acid RNA RNA, Viral - genetics Treatment Outcome Young Adult 내과학 |
| title | High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T06%3A23%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20effectiveness%20of%20peginterferon%20alfa-2a%20plus%20ribavirin%20therapy%20in%20Korean%20patients%20with%20chronic%20hepatitis%20C%20in%20clinical%20practice&rft.jtitle=Clinical%20and%20molecular%20hepatology&rft.au=Heo,%20Nae-Yun&rft.date=2013-03-01&rft.volume=19&rft.issue=1&rft.spage=60&rft.epage=69&rft.pages=60-69&rft.issn=2287-2728&rft.eissn=2287-285X&rft_id=info:doi/10.3350/cmh.2013.19.1.60&rft_dat=%3Cproquest_nrf_k%3E3126718788%3C/proquest_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c523t-cf40b99ed7e3b1aff8fbf83f22b379cc4563466814e46e883dfaa13307ef4ac93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3126718788&rft_id=info:pmid/23593611&rfr_iscdi=true |